skip navigation nih record
Vol. LXV, No. 11
May 24, 2013
cover

previous story



Seen

Members of Congress Visit NIH, Get Science Briefing
Photos: Ernie Branson

NIH director Dr. Francis Collins (l) greets Rep. Eric Cantor (R-VA).
NIH director Dr. Francis Collins (l) greets Rep. Eric Cantor (R-VA).

A bipartisan delegation of 9 members of Congress, led by House majority leader Rep. Eric Cantor (R-VA), visited the Clinical Center on May 9.

After overviews in the CRC lobby by NIH director Dr. Francis Collins and CC director Dr. John Gallin, the group shared a working lunch with NIH leadership.

Afterwards, they were led on a tour of NCI’s Laboratory of Molecular Biology of Lymphoid Malignancies, where Dr. Louis Staudt, deputy chief of the Metabolism Branch in the Center for Cancer Research, briefed them on his research.

“[I explained] how a precise molecular diagnosis of cancer can lead to targeted therapies that produce remissions while having few side effects,” he noted. “I provided an example from our ibrutinib trial in which one woman whose tumor was refractory to chemotherapy went into a complete remission that has so far lasted more than 2.5 years. We have overall a 41 percent response rate in the ABC subtype of diffuse large B cell lymphoma.”

In the NCI Laboratory of Molecular Biology of Lymphoid Malignancies, members of Congress take in a briefing by Dr. Louis Staudt (r), deputy chief of the Metabolism Branch.

Above: In the NCI Laboratory of Molecular Biology of Lymphoid Malignancies, members of Congress take in a briefing by Dr. Louis Staudt (r), deputy chief of the Metabolism Branch. Below: At left, Rep. Chaka Fattah (D-PA) peers through a microscope as postdoctoral fellow Dr. Anna Mazzucco explains which lymphoma cells have been treated with the drug ibrutinib. Staudt and colleagues are using the drug in clinical trials. At right, Collins (c) leads a working lunch with NIH leadership including (from l) NCATS director Dr. Chris Austin, CC director Dr. John Gallin, NIH principal deputy director Dr. Lawrence Tabak, NIH deputy director for science, outreach and policy Dr. Kathy Hudson, NIAID director Dr. Anthony Fauci and NHLBI director Dr. Gary Gibbons.

Rep. Chaka Fattah (D-PA) peers through a microscope as postdoctoral fellow Dr. Anna Mazzucco explains which lymphoma cells have been treated with the drug ibrutinib. Staudt and colleagues are using the drug in clinical trials.
Collins (c) leads a working lunch with NIH leadership including (from l) NCATS director Dr. Chris Austin, CC director Dr. John Gallin, NIH principal deputy director Dr. Lawrence Tabak, NIH deputy director for science, outreach and policy Dr. Kathy Hudson, NIAID director Dr. Anthony Fauci and NHLBI director Dr. Gary Gibbons.
in the Medical Board Room, Cantor (third from l) and colleagues (from l) Congressman Earl Blumenauer (D-OR), Rep. Ted Yoho (R-FL) and Congressman Michael Burgess (R-TX) share lunch.
Congresswoman Renee Ellmers (l, R-NC) talks with Mazzucco and staff scientist Dr. Ryan Young, as he explains the experiment he set up for the tour. He took a cell line model of the ABC subtype of diffuse large B cell lymphoma and treated it (or not) with ibrutinib. The ibrutinib killed the cancer cells in the culture wells, just as it kills lymphoma cells in the Staudt lab’s phase II clinical trial.

At left, in the Medical Board Room, Cantor (third from l) and colleagues (from l) Congressman Earl Blumenauer (D-OR), Rep. Ted Yoho (R-FL) and Congressman Michael Burgess (R-TX) share lunch. At right, Congresswoman Renee Ellmers (l, R-NC) talks with Mazzucco and staff scientist Dr. Ryan Young, as he explains the experiment he set up for the tour. He took a cell line model of the ABC subtype of diffuse large B cell lymphoma and treated it (or not) with ibrutinib. The ibrutinib killed the cancer cells in the culture wells, just as it kills lymphoma cells in the Staudt lab’s phase II clinical trial.


back to top of page